Drug intelligence / Profile preview

IN001

Development stage: Phase 2
Lead developer: Shenzhen Shenxin Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Injection

Overview

IN001 is an mRNA vaccine developed by Shenzhen Shenxin Biotechnology Co., Ltd for the prevention of Herpes Zoster. It is designed to evaluate its safety, tolerability, and immunogenicity in healthy participants. The vaccine is administered via injection and aims to stimulate the immune system to react against the Herpes Zoster virus.

Other names: Herpes Zoster IN001 mRNA VaccineHZ Vaccine (IN001)

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on IN001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN001.

Explore the full profile